Hepatología: porfirias y carcinogénesis
Publikationen (8) Publikationen, an denen Forscher/innen teilgenommen haben
filter_list
2025
-
FGF21 and APOA1 mRNA-based therapies for the treatment of experimental acute pancreatitis
Journal of Translational Medicine, Vol. 23, Núm. 1
-
Porphyrins and the porphyrias
Liver International
-
RNA-based therapies in liver metabolic diseases
Gut
-
Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates
Gut, Vol. 74, Núm. 2, pp. 270-283
2024
-
Exploring current and emerging therapies for porphyrias
Liver International, Vol. 44, Núm. 9, pp. 2174-2190
-
Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)
Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284
-
Porfirias.
Medicina interna (Elsevier España), pp. 1865-1873
-
The Alpha-Lipoic Acid Improves Glucose Metabolism and Hyperinsulinemia in Acute Intermittent Porphyria: A Nutritional Concept for the Management of Rare Disorders
Cellular and Molecular Gastroenterology and Hepatology